Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling ...

Harrow's focused acquisition model in ophthalmic drugs enables high growth, with a diversified portfolio and limited R&D expenses. My DCF analysis suggests a fair value of $72.75 per share—nearly 100% ...

Harrow has two outstanding notes on offer that come up for maturity in 2026 and 2027. The 11.875% Senior Notes due 2027 offer a compelling 11.5% yield on cost and trade at a just under 3% premium to ...